Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

The FDA has approved the therapy as a treatment for psoriatic arthritis and ankylosing spondylitis, the Swiss drugmaker said Friday, noting that in the U.S., up to 1% of the general population may be affected by psoriatic arthritis. Half a million are

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.